OptiBiotix Health inks license agreement with Tenshindo in Japan

Writer, Stock Market Wire
Wednesday, July 3, 2019 - 07:54

OptiBiotix Health said subsidiary ProBiotix Health had signed a non-exclusive license agreement with Tenshindo for the use of Lactobacillus plantarum in cardiovascular food supplements in Japan.

Tenshindo was a manufacturer of functional food and cosmetics products founded in Japan in 1986.

Lactobacillus plantarum would be the active ingredient in a novel cardiovascular health product that Tenshindo would add to its current portfolio of over 50 products.

Tenshindo and ProBiotix would work together to obtain an authorised cardiovascular health claim from Japanese authorities, based on the existing clinical and market evidence on the strain.


Related content

OptiBiotix Health gets key validation for probiotic product

OptiBiotix Health said subsidiary ProBiotix Health had completed process validation under pharmaceutical good manufacturing practices for its probiotic product as a drug substance.

The company...

Wed, 09/10/2019 - 07:33


OptiBiotix Health inks distribution pact for South Africa, neighbouring countries

OptiBiotix Health said it had entered into a one-year exclusive distribution agreement with a South African partner for its consumer weight-management products in South Africa...

Wed, 18/09/2019 - 07:48


OptiBiotix Health books first-half loss as it inks more distribution pacts

Dietry supplement group for weight loss and cholesterol control OptiBiotix Health booked a first-half loss after modest sales were offset by administrative costs.

Pre-tax losses...

Wed, 28/08/2019 - 08:01


OptiBiotix Health inks distribution pact in Australia, NZ with Maxum Foods

OptiBiotix Health said it had entered into a manufacturing, supply and distribution agreement with Maxum Foods for its weight management technology in Australia and New...

Mon, 12/08/2019 - 08:01


OptiBiotix Health inks licencing agreement with Kappa Bioscience

OptiBiotix Health said subsidiary ProBiotix Health had signed a license agreement with Kappa Bioscience.

The agreement covered the use of OptiBiotix Health's blood pressure-reducing probiotic...

Mon, 01/07/2019 - 08:51